CDMO Sterling burnishes its U.S. credentials with buyout of North Carolina facility

Sterling Pharma Solutions has acquired a complex chemistry operation in Cary, North Carolina, with 23 employees. (Sterling Pharma Solutions)

With two-thirds of its customers in the U.S., Sterling Pharma Solutions figured it should have a facility there. So the U.K.-based CDMO bought one.

The small molecule API maker said this week it has acquired the Cary, North Carolina, location of CiVentiChem, retaining 23 employees and giving Sterling its first U.S. facility and the ability to provide chemical development more easily to its clients.

"The North American market now makes up 70% of our customer portfolio which was one of the major reasons behind the decision to look for a facility in the U.S.,” Sterling CEO Kevin Cook said in a statement.

On-Demand Webinar

De-Risking the Solid Form Landscape of an API

This presentation will discuss how predictable stability and solubility can minimize development timelines and cost. Attend to hear about two case studies exemplifying the importance of understanding the hydration space of an API and how hydrate formation may be avoided by development of a robust crystallization procedure.

The facility in Cary has development laboratories and kilo scale cGMP suites for complex chemistry work. Terms of the deal were not disclosed, but the two companies said CiVentiChem will continue to operate out of its own facility in India as a separate entity from Sterling.

The acquisition by the Newcastle upon Tyne-based Sterling comes just weeks after a management buyout involving European private investment firm GHO Capital. GHO noted Sterling’s expertise in complex chemistry when announcing the deal.

Sterling was itself created in 2016 through a buyout by managers of a nearly 50-year-old facility in Dudley, U.K., from Strides Shasun. Cook has worked at the site for more than 20 years.

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.